FARGO, N.D. — Aldevron and Minaris have renewed a licensing agreement intended to expand access to a lentiviral plasmid system used in gene-modified cell therapy development.
Aldevron, a Danaher company that produces DNA, RNA and protein for genomic medicine, and Minaris, a global cell and gene therapy contract development and manufacturing organization, said the agreement covers a proprietary, off-the-shelf lentiviral plasmid system for gene-modified cell therapy applications.
The companies said the renewed agreement is designed to help therapy developers simplify supply chains, reduce risk and move programs from discovery to the clinic more quickly.
The agreement builds on Aldevron’s partnership with Oxgene, a Minaris brand whose lentiviral plasmid designs have been used across the cell and gene therapy sector. Under the renewed deal, Aldevron will continue to manufacture and offer the plasmids across research, GMP Source quality grade and full cGMP.
The companies said the arrangement gives clients access to regulatory-ready starting materials and to the Oxgene Development Centre in London, where experts can further optimize plasmids and genes of interest to improve viral vector productivity and process performance.
Aldevron’s pALD-Lenti plasmid system is a four-plasmid platform optimized for lentiviral vector production. It supports applications including CAR-T, TCR-T and other gene-modified cell therapies. Aldevron said offering the system off the shelf at multiple quality grades can help reduce lead times and accelerate development timelines.
“Our collaboration with Minaris brings together complementary strengths—world-class plasmid design and cGMP manufacturing innovation—in a way that reduces risk and complexity for developers at every stage of the pipeline,” said Venkata Indurthi, Chief Science Officer for Aldevron. “By delivering phase appropriate starting materials backed by deep manufacturing and quality expertise, Aldevron is helping compress development timelines and move innovative therapies from discovery to the clinic with greater speed, confidence, and scalability.”
Oxgene serves as Minaris’ innovation engine and center of excellence for advanced technologies, including viral vectors through its TESSA AAV and XOFLX LVV platforms. The company provides expertise in vector design, plasmids and cell line development as part of Minaris’ broader CDMO capabilities.
“Through our Oxgene Center of Excellence in London, we bring deep expertise in plasmid design and engineering that is grounded in real-world vector development and manufacturing experience,” said Eytan Abraham, PhD, Chief Technology and Commercial Officer, Minaris. “Our focus has always been on designing robust, high-performing plasmid systems that translate seamlessly into scalable vector production. By combining that design expertise with Aldevron’s manufacturing strength, we help ensure developers have reliable, high-quality starting materials that reduce risk, streamline development, and support a clear path toward clinical and commercial success.”
The companies said the agreement reflects Aldevron’s focus on providing consistent, scalable and high-quality plasmid DNA solutions for gene-modified cell therapy programs.
